NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
CAMBRIDGE, Mass., Feb. 17, 2016 -- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, February 24, 2016 at 8:30 AM ET to report its fourth quarter and full year 2015 financial results and discuss recent business updates.
The live webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. The conference call can be accessed by dialing 1-866-450-8683 (toll-free domestic) or 1-281-542-4847 (international) and using the conference ID 49865237. A replay of the webcast will be available on Sage’s website approximately two hours after the completion of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. Sage is developing its next generation modulators, including SAGE-217, SAGE-689 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.
Investor Contact: Paul Cox, Sage Therapeutics [email protected] 617-299-8377 Media Contact: Maureen L. Suda, Suda Communications LLC [email protected] 585-387-9248
